Recent News

• 04.08.2025 - Yun Zhong, Ph.D.
• 04.08.2025 - Yun Zhong, Ph.D.
• 03.26.2025 - 48-Week Results from FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
• 03.26.2025 - 48-Week Results from FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
• 03.26.2025 - Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
• 03.26.2025 - Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
• 03.26.2025 - Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
• 03.04.2025 - Wave Life Sciences Fourth Quarter 2024 Earnings Call
• 03.04.2025 - Wave Life Sciences Fourth Quarter 2024 Earnings Call
• 03.04.2025 - Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Recent Filings

• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 8-K Current report
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - 144 Report of proposed sale of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 144 Report of proposed sale of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities